Genetic variation and response to morphine in cancer patients: Catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects

Cancer

Volumn 112, Issue 6, 2008, Pages 1390-1403

  Ross, Joy R ^a,b   Riley, Julia ^c   Taegetmeyer, Annie B ^b   Sato, Hiroe ^b   Gretton, Sophy ^b,c   Du Bois, Roland M ^b   Welsh, Kenneth I ^b  

^a St Joseph's Hospice   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Cancer; Catechol O methyltransferase gene; Morphine; Multidrug resistance 1 gene; Pain; Polymorphism; Side effects

Indexed keywords

ADENOSINE; AMINO ACID; CATECHOL METHYLTRANSFERASE; DRUG METABOLITE; MORPHINE; MULTIDRUG RESISTANCE PROTEIN 1; OPIATE; OXYCODONE; THYMIDINE;

ADULT; ADVERSE OUTCOME; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD BRAIN BARRIER; CANCER PAIN; CANCER PATIENT; CHI SQUARE TEST; CONCENTRATION (PARAMETERS); CONFUSION; CONSTIPATION; CONTROLLED STUDY; DROWSINESS; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG UPTAKE; EXON; FEMALE; GENETIC CORRELATION; GENETIC VARIABILITY; GENOTYPE; HALLUCINATION; HAPLOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MYOCLONUS; NAUSEA; NIGHTMARE; PHARMACOGENETICS; PRIORITY JOURNAL; PRURITUS; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; XEROSTOMIA;

ALLELES; CASE-CONTROL STUDIES; CATECHOL O-METHYLTRANSFERASE; COHORT STUDIES; FEMALE; GENOTYPE; HUMANS; INTRONS; MALE; MIDDLE AGED; MORPHINE; NARCOTICS; NEOPLASMS; P-GLYCOPROTEIN; PAIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SLEEP STAGES; VARIATION (GENETICS);

EID: 41149145156     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23292     Document Type: Article

References (47)

1. World Health Organization. Cancer Pain Relief, 2nd ed. Geneva, Switzerland: World Health Organization; 1996.
2. Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001;19:2542-2554.
3. Cherny NJ, Chang V, Frager G, et al. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer. 1995;76:1283-1293.
4. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev. 2004;(3)CD004847.
5. Riley JL, Ross JR, Rutter D, et al. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid. Support Care Cancer. 2006;14:56-64.
6. Evans WE. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit. 2004;26:186-191.
7. Sindrup SH, Brosen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics. 1995;5:335-346.
8. Caraco Y, Sheller J, Wood AJ. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. J Pharmacol Exp Ther. 1996;278:1165-1174.
9. Rana BK, Shiina T, Insel PA. Genetic variations and polymorphisms of G protein-coupled receptors: functional and therapeutic implications. Annu Rev Pharmacol Toxicol. 2001;41:593-624.
10. Keith DE, Anton B, Murray SR, et al. Mu-opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Mol Pharmacol. 1998;53:377-384.
11. Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG. Mu-opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence. Nature. 2000;408:720-723.
12. Cen B, Xiong Y, Ma L, Pei G. Direct and differential interaction of beta-arrestins with the intracellular domains of different opioid receptors. Mol Pharmacol. 2001;59:758-764.
13. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT. Enhanced morphine analgesia in mice lacking β-arrestin2. Science. 1999;286:2495-2498.
14. Yu Y, Zhang L, Yin X, Sun H, Uhl GR, Wang JB. Mu opioid receptor phosphorylation, desensitization, and ligand efficacy. J Biol Chem. 1997;272:28869-28874.
15. Ross JR, Rutter D, Welsh KI, et al. Clinical response to morphine in cancer patients and variation in candidate genes. Pharmacogenomics J. 2005;5:324-336.
16. Thompson SJ, Koszdin K, Bernards CM. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology. 2000;92:1392-1399.
17. Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol. 1997;3:161-170.
18. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75:13-33.
19. Peyron R, Laurent B, Garcia-Larrea L. Functional imaging of brain responses to pain. A review and meta-analysis. Neurophysiol Clin. 2000;30:263-288.
20. Jordan BA, Gomes I, Rios C, Filipovska J, Devi LA. Functional interactions between mu opioid and alpha 2A-adrenergic receptors. Mol Pharmacol. 2003;64:1317-1324.
21. Steiner H, Gerfen CR. Dynorphin opioid inhibition of cocaine-induced, D1 dopamine receptor-mediated immediate-early gene expression in the striatum. J Comp Neurol. 1995;353:200-212.
22. Steiner H, Gerfen CR. Enkephalin regulates acute D2 dopamine receptor antagonist-induced immediate-early gene expression in striatal neurons. Neuroscience. 1999;88:795-810.
23. Chen JF, Aloyo VJ, Weiss B. Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum. Neuroscience. 1993;54:669-680.
24. Zubieta JK, Heitzeg MM, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 2003;299:1240-1243.
25. Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry. 1995;34:4202-4210.
26. Palmatier MA, Pakstis AJ, Speed W, et al. COMT haplotypes suggest P2 promoter region relevance for schizophrenia. Mol Psychiatr. 2004;9:859-870.
27. Shifman S, Bronstein M, Sternfeld M, et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet. 2002;71:1296-1302.
28. Handoko HY, Nyholt DR, Hayward NK, et al. Separate and interacting effects within the catechol-O-methyltransferase (COMT) are associated with schizophrenia. Mol Psychiatr. 2005;10:589-597.
29. Bray NJ, Buckland PR, Williams NM, et al. A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am J Hum Genet. 2003;73:152-161.
30. Chen J, Lipska BK, Halim N, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet. 2004;75:807-821.
31. Diatchenko L, Slade GD, Nackley AG, et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet. 2005;14:135-143.
32. Rakvag TT, Mepstad P, Baar C, et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain. 2005;116(1-2):73-78.
33. Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983;17:197-210.
34. Li T, Xu K, Deng H, et al. Association analysis of the dopamine D4 gene exon III VNTR and heroin abuse in Chinese subjects. Mol Psychiatr. 1997;2:413-416.
35. Dowman R. Topographic analysis of painful laser and sural nerve electrical evoked potentials. Brain Topogr. 2004;16:169-179.
36. Ahmad T, Neville M, Marshall SE, et al. Haplotype-specific linkage disequilibrium patterns define the genetic topography of the human MHC. Hum Mol Genet. 2003;12:647-656.
37. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics. 2003;4:397-410.
38. Okamura N, Sakaeda T, Okumura K. Pharmacogenomics of MDR and MRP subfamilies. Personalized Med. 2004;1:85-104.
39. Kroetz DL, Pauli-Magnus C, Hodges LM, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics. 2003;13:481-494.
40. Svejgaard A, Jersild C, Nielsen LS, Bodmer WF. HL-A antigens and disease. Statistical and genetical considerations. Tissue Antigens. 1974;4:95-105.
41. Kim H, Lee H, Rowan J, Brahim J, Dionne RA. Genetic polymorphisms in monoamine neurotransmitter systems show only weak association with acute post-surgical pain in humans. Mol Pain [serial online]. 2006;2:24.
42. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70:189-199.
43. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C. MDR-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res. 2006;12(3 pt 1):854-859.
44. Lamba J, Strom S, Venkataramanan R, et al. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther. 2006;79:325-338.
45. Gitlin MC, Taylor BK, Kalarickal PL, Lonseth ED. Does dysregulation of catechol-O-methyltransferase predispose to opioid-induced hallucinations? A report of a patient with microdeletion of chromosome 22 and opioid-associated hallucinations. Pain Med. 2006;8:84-86.
46. DeMille MM, Kidd JR, Ruggeri V, et al. Population variation in linkage disequilibrium across the COMT gene considering promoter region and coding region variation. Hum Genet. 2002;111:521-537.
47. Holthe M, Rakvag TN, Klepstad P, et al. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J. 2003;3:17-26.